1. Must be a newly diagnosed and untreated patient with Ph+ B-cell Acute Lymphoblastic
Leukemia and CD22 expression on ≥20% of blasts.
2. 18 years old or older.
3. Bone marrow involvement with ≥20% lymphoblasts and demonstration of BCR-ABL1 via
fluorescence in situ hybridization (FISH) studies or PCR-based testing. Patients with
>1000/mm3 lymphoblasts in the peripheral blood that cannot undergo bone marrow biopsy
and aspiration due to clinical condition are also eligible.
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
5. Adequate organ function as confirmed by clinical/medical record.
6. Patients must be at least 2 weeks from major surgery, radiation therapy, or
participation in other investigational trials, and must have recovered from clinically
significant toxicities related to these prior treatments.
7. Patients must voluntarily sign and date an informed consent, approved by an
Independent Ethics Committee/Institutional Review Board prior to starting any
screening or study-specific procedures.
8. Females of childbearing potential will use effective contraception during treatment
with InO and for at least 8 months after the last dose. Males with female partners of
reproductive potential will use effective contraception during treatment with
Inotuzumab Ozogamicin and for at least 5 months after the last dose. A patient is of
childbearing potential if, in the opinion of the treating investigator, he/she is
biologically capable of having children and is sexually active. Female patients who
are not of childbearing potential (ie, meet at least one of the following criteria):
a. Have undergone hysterectomy or bilateral oophorectomy; or have medically confirmed
ovarian failure; or are medically confirmed to be post-menopausal (cessation of
regular menses for at least 12 consecutive months with no alternative pathological or
9. Patients who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
1. Isolated extramedullary disease.
2. Burkitt's or mixed-lineage leukemia.
3. Active central nervous system (CNS) leukemia.
4. Any prior therapy for ALL except for limited treatment (≤ 7 days) with corticosteroids
or hydroxyurea and a single dose of intrathecal therapy. Patients who are being
treated with chronic steroids for other reasons (eg, asthma, autoimmune disorders) are
5. Current or chronic hepatitis B or C infection as evidenced by hepatitis B surface
antigen and anti-hepatitis C antibody positivity, respectively, or known
seropositivity for human immunodeficiency virus (HIV). HIV testing may need to be
performed in accordance with local regulations or local practice. Patients with HIV
but an undetectable viral load are eligible for enrollment
6. Major surgery within ≤ 2 weeks before randomization.
7. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function or
unstable pulmonary condition.
8. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of
the cervix, or localized prostate cancer that has been definitely treated with
radiation or surgery. Patients with previous malignancies are eligible provided that
they have been disease free for ≥2 years or are not currently requiring treatment.
9. Uncontrolled cardiac disease.
10. QTcF > 500 msec (based on the average of 3 consecutive ECGs).
11. History of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse.
12. History of hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome
13. Evidence of uncontrolled current serious active infection including sepsis,
bacteremia, fungemia, or patients with a recent history (within 4 months) of deep
tissue infections such as fasciitis or osteomyelitis.
14. Medications known to predispose to Torsades de Pointes are prohibited throughout the
treatment period of the study.
15. Pregnant females; breastfeeding females; males with female partners of reproductive
potential and females of childbearing potential not using highly effective
contraception or not agreeing to continue highly effective contraception for a minimum
of 5 months after the last dose of investigational product if male and 8 months after
the last dose of investigational product if female.
16. Patients who are investigational site staff members or relatives of those site staff
members or patients who are Pfizer employees directly involved in the conduct of the
17. Participation in other investigational studies during active treatment phase.
18. Other severe acute, chronic medical, psychiatric condition, or laboratory abnormality
that may increase the risk associated with study participation or investigational
product administration or may interfere with the interpretation of study results and,
in the judgment of the Study Lead Principal Investigator, would make the patient
inappropriate for entry into this study.